US OptionsDetailed Quotes
MNKD250103C7500
- 0.05
- -0.05-50.00%
15min DelayClose Jan 3 16:00 ET
0.05High0.05Low
0.05Open0.10Pre Close1 Volume41 Open Interest7.50Strike Price5.00Turnover5818.74%IV16.51%PremiumJan 3, 2025Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1321Delta0.2696Gamma129.60Leverage Ratio-52.1538Theta0.0000Rho17.12Eff Leverage0.0000Vega
MannKind Stock Discussion
Sign in to post a comment
$MannKind (MNKD.US)$
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
4 minutes ago, 3:05 AM PST
Via GlobeNewswire
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025
Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression
MannKind (MNKD) announced six-month results from its Phase 3 INHALE-1 study of Afrezza (inhaled insulin) in children and adolescents aged 4-17...
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
4 minutes ago, 3:05 AM PST
Via GlobeNewswire
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025
Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression
MannKind (MNKD) announced six-month results from its Phase 3 INHALE-1 study of Afrezza (inhaled insulin) in children and adolescents aged 4-17...
1
Surpassed target price and am focusing elsewhere.
5
1
I think this company still has room to grow and may be undervalued, however it is next to being scaling out for other opportunities as the space is crowded and many new therapies have advanced.
2
1
I think $United Natural Foods (UNFI.US)$
is still undervalued. Originally purchased as a longterm hold, I intend to sell instead at ~25 USD and put the capital toward other trades, likely CSPs focusing on other equities for longterm holds.
A speculative hold for the longterm, though may take profit if another opportunity beckons. This is the same approach as to $MannKind (MNKD.US)$ and $Iovance Biotherapeutics (IOVA.US)$ :
Two speculative positions that I am building (similar ...
is still undervalued. Originally purchased as a longterm hold, I intend to sell instead at ~25 USD and put the capital toward other trades, likely CSPs focusing on other equities for longterm holds.
A speculative hold for the longterm, though may take profit if another opportunity beckons. This is the same approach as to $MannKind (MNKD.US)$ and $Iovance Biotherapeutics (IOVA.US)$ :
Two speculative positions that I am building (similar ...
+3
11
1
These calls performed well in theory, but I was unable to get a fill at maximum profit, which was about 90%. I’ve learned a realted lesson a few times. It’s key to trade options with a great deal of liquidity. (Or pay a fee for more obscure tickers, in order to get a more beneficial fill.) I now largely trade more popular contracts and use LEAPS to speculate in the longer term on less heavily traded equities; treating them as less capital intensive share proxies, to be traded at a ...
loading...
3
No longer adding as I’ve a great deal of exposure to the space. A medium term hold, performing well.
2
$MannKind (MNKD.US)$ woohey I stopped out quick on that drop
Exited MNKD calls up 40%, exiting SMCI short, exiting Chewy lottos. Long Nvidia, buying ASTS shares, holding UVXY December calls as a hedge (and will buy more when cheap.) Adding to leveraged BTC ETF.
9
3
No comment yet
Stock_Drift OP : $MannKind (MNKD.US)$
下一个十年的雷熊 : Seems favorable. Strange, there isn't much movement ahead of the market![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")